Feb 17, 2023 / 09:30PM GMT
Operator
Thank you for standing by, and welcome to the Apellis SYFOVRE FDA approval conference call. (Operator Instructions) As a reminder, today's conference is being recorded.
I would now like to hand the conference over to your host, Meredith Kaya. Please begin.
Meredith Kaya - Apellis Pharmaceuticals, Inc. - SVP, IR & Strategic Finance
Thank you for joining us today to discuss the FDA approval of intravitreal pegcetacoplan, now with the brand name SYFOVRE, as the first and only treatment for geographic atrophy, or GA.
With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Medical Officer, Dr. Caroline Baumal; and Chief Commercial Officer, Adam Townsend. Tim Sullivan, Chief Financial Officer, will be available for the Q&A.
Before we begin, I would like to point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to
Apellis Pharmaceuticals Inc SYFOVRE FDA Approval Call Transcript
Feb 18, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers